Summary
Intuitive Surgical, Inc. (ISRG) reported strong financial performance for the nine months ended September 30, 2012, with total revenue increasing by 24.5% to $1.57 billion compared to the same period in 2011. This growth was driven by increased adoption of da Vinci Surgical Systems and a robust rise in recurring revenue from instruments, accessories, and services, which now constitute 57% of total revenue. The company also demonstrated solid operational efficiency, with operating income growing by 27% year-over-year. Despite a slowdown in European markets due to economic pressures and a decline in U.S. prostatectomy procedures, the company's overall revenue and procedure growth remain positive, supported by expanding gynecologic and general surgery procedures in the U.S. and international system sales. Financially, ISRG maintained a strong balance sheet with $2.7 billion in cash, cash equivalents, and investments as of September 30, 2012. The company continued to generate significant cash flow from operations ($597.0 million for the nine months ended Sept 30, 2012) and managed its capital effectively, including executing a share repurchase program. The company's strategic focus on new product introductions and market expansion, coupled with a growing installed base of da Vinci systems, positions it well for continued growth, although ongoing European economic uncertainties and shifts in prostatectomy treatment patterns present areas for investor monitoring.
Financial Highlights
46 data points| Revenue | $537.80M |
| Cost of Revenue | $147.70M |
| Gross Profit | $390.10M |
| R&D Expenses | $49.70M |
| SG&A Expenses | $129.00M |
| Operating Expenses | $178.70M |
| Operating Income | $211.40M |
| Net Income | $183.30M |
| EPS (Basic) | $0.51 |
| EPS (Diluted) | $0.50 |
| Shares Outstanding (Basic) | 359.10M |
| Shares Outstanding (Diluted) | 369.90M |
Key Highlights
- 1Total revenue for the nine months ended September 30, 2012, increased by 24.5% to $1.57 billion, up from $1.26 billion in the prior year.
- 2Recurring revenue grew by 27.5% year-over-year to $901.5 million for the nine months ended September 30, 2012, representing 57% of total revenue, indicating strong customer utilization and service contract renewals.
- 3The installed base of da Vinci Surgical Systems expanded to 2,462 as of September 30, 2012, an increase from 2,031 in the prior year.
- 4Instruments and accessories revenue saw a significant increase of 28.7% to $649.5 million for the nine months ended September 30, 2012, driven by higher procedure volumes and new product introductions.
- 5Net income for the nine months ended September 30, 2012, rose to $481.7 million from $343.9 million in the comparable period of 2011, a 40% increase.
- 6The company maintained a strong liquidity position with $2.7 billion in cash, cash equivalents, and investments as of September 30, 2012.
- 7Despite positive overall trends, U.S. da Vinci Prostatectomy (dVP) procedures declined approximately 20% in Q3 2012 compared to Q3 2011, attributed to changes in PSA testing recommendations and non-surgical disease management.